PCT Protocols

Question 1

When should I start PCT after my last Testosterone Enanthate injection?

Accepted Answer

Day 14 post-last-injection. That is the answer. The reasoning matters — it drives how you handle short esters, mixed cycles, and 19-nors with entirely different kinetics. The kinetics Testosterone Enanthate: t½ ≈ 4.5 days IM. Five half-lives to reach functional clearance. Serum concentrations at post-last-injection intervals: Day 7: 50% of peak still circulating Day 14: 25% — SERM signalling begins to register at the pituitary Day 21: 6–12% — effectively baseline for recovery purposes Starting SERMs at day 7 is wasted medication — the hypothalamus still reads suppressive androgen load and will not resume GnRH pulsing. Starting at day 21 leaves an additional week of HPTA inactivity before recovery stimulus arrives. Day 14 is the compromise the published protocols converge on. Cypionate t½ 8 days. The 14-day rule holds; some conservative protocols extend to day 16–18. The difference is negligible. Short esters — Propionate, Trenbolone Acetate Propionate t½ is 0.8&hellip;

Question 2

Clomid vs Nolvadex — which one do I actually need?

Accepted Answer

Both are SERMs. Both block estrogen feedback at the hypothalamus and drive LH/FSH output. The receptor-level difference determines side profile, dose tolerance, and which one fits which cycle. Clomiphene Citrate (Clomid) Triphenylethylene structure. Mixed agonist-antagonist at ER. The trans isomer (enclomifene) is the anti-estrogenic fraction driving HPTA recovery; the cis isomer (zuclomifene) is estrogenic, long half-life, and responsible for the ocular and mood side profile. Pharmacy Clomid is a 60:40 trans:cis mixture. Clinical use: Aggressive LH drive. First-line for deeply suppressed HPTA — long cycles, high-dose blast protocols, 19-nor-containing cycles. Documented to produce 3–4× baseline LH within 72 hours of initiation. Side-effect profile: Visual disturbance (light sensitivity, floaters, rarely persistent after-images) in 5–10% of users; vision sides indicate cumulative zuclomifene load and mandate immediate discontinuation — recovery over weeks, not days. Mood lability in a separate 10–15% subset: irritability, anxiety, depressive episodes, occasional emotional incontinence. Dose-dependent. Tamoxifen (Nolvadex) Triphenylethylene metabolite.&hellip;

Question 3

Do I need HCG during cycle or just in PCT?

Accepted Answer

Human chorionic gonadotropin (hCG) is a glycoprotein hormone structurally homologous to LH across the α-subunit and functionally homologous at the LH receptor on Leydig cells. In protocol design hCG occupies one of three roles — preservation (on-cycle), initiation (pre-PCT blast), or salvage (post-PCT rescue). These are different interventions targeting different problems. Mechanism Exogenous testosterone suppresses hypothalamic GnRH pulsing. Without GnRH, the pituitary stops secreting LH. Without LH signal, Leydig cells downregulate steroidogenic enzyme expression (CYP11A1, HSD3B2, CYP17A1) and atrophy follows. The damage scales with suppression duration — 8 weeks produces reversible downregulation, 6+ months produces the Leydig-cell desensitisation picture that resists SERM-only PCT. hCG binds the LH receptor and reactivates the full steroidogenic cascade without requiring hypothalamic input. It is pharmacological bypass of the central signal. On-cycle hCG — preservation protocol 500 IU 2× weekly (or 250 IU 3× weekly) throughout suppression. Mechanism is maintenance, not restoration — Leydig cells&hellip;

Question 4

How long does it take for testosterone levels to recover after a cycle?

Accepted Answer

Recovery timeline is a distribution, not a deadline. The median user on a standard first cycle recovers to 80% of baseline total testosterone at week 8–10 post-PCT. The tail extends further — 5–10% of users at week 12, a smaller fraction beyond 16 weeks, and a residual population that never reaches pre-cycle baseline. Cycle duration, compound profile, prior suppression exposure, and on-cycle hCG status all shift the distribution. First cycle, SERM-based PCT 10–12 week cycle, ≤500 mg/week testosterone, 4-week SERM PCT: Week 4 post-PCT: Total T 300–500 ng/dL in most responders. LH and FSH rising and detectable. Week 6–8: Total T within 20% of pre-cycle baseline in roughly 70% of users. The decision panel point. Week 10–12: Near-complete serum recovery in the median user. Libido, mood, and energy lag 2–4 weeks behind the numbers — SHBG rebound and tissue-level androgen receptor resensitisation run on separate clocks. Second and later cycles&hellip;

Question 5

What is the minimum PCT for a first cycle?

Accepted Answer

Floor and optimum are different decisions. The defensible floor for a first 12-week testosterone-enanthate cycle at ≤500 mg/week is tamoxifen 20 mg/day × 4 weeks, started 14 days after the last injection. The optimum adds clomiphene to the protocol and tightens the timing around bloodwork verification rather than calendar guesswork. Why tamoxifen alone clears the floor Tamoxifen is a SERM with antagonist activity at hypothalamic and pituitary estrogen receptors. The mechanism: hypothalamic ERα binds circulating estradiol and translates that signal into negative feedback on GnRH pulsing. Block the receptor, the feedback brake releases, GnRH pulsing resumes, and pituitary LH and FSH secretion follows. The testes — assuming they remain LH-responsive — restart endogenous testosterone synthesis. First-cycle HPTA suppression is the shortest-duration, easiest-to-restart variant. Twelve weeks of testosterone exposure produces measurable but reversible Leydig-cell desensitisation. The cells retain steroidogenic enzyme expression and respond to restored LH signal within 2–4 weeks of&hellip;

Question 6

Do I need an aromatase inhibitor on every cycle?

Accepted Answer

No. AI prophylaxis on every cycle is the default protocol assumption that produces more clinical morbidity than the elevated estradiol it was meant to prevent. The intervention has a mechanism, a measurable target range, and a documented over-suppression syndrome — using it requires matching all three to the situation, not adding it reflexively to every protocol. What aromatase inhibitors actually do CYP19A1 (aromatase) is the enzyme that converts C19 androgens (testosterone, androstenedione) to C18 estrogens (estradiol, estrone). The enzyme is expressed primarily in adipose tissue, with secondary expression in central nervous system, bone, and gonads. Conversion rate at physiological substrate: ~0.2–0.3% of testosterone aromatises to estradiol per pass. AI binds the enzyme active site and prevents the substrate-binding step. Anastrozole and letrozole are competitive reversible inhibitors; exemestane is a suicide (irreversible) inhibitor. All three reduce circulating estradiol — exemestane more durably (recovery requires new enzyme synthesis), anastrozole and letrozole reverse&hellip;

Question 7

Gyno symptoms on cycle — Nolvadex or letrozole?

Accepted Answer

Intervention matches the stage and the mechanism. Early receptor-mediated sensitivity responds to tamoxifen alone; established glandular tissue with palpable mass requires combined AI+SERM; fibrosed chronic tissue requires surgical excision and pharmacological approaches are no longer reversing it. Stage-matching is what distinguishes successful intervention from compound-stacking that fails. Tissue differential — what you are actually palpating Three distinct presentations get labelled "gyno" on forums, and they require different responses: True gynaecomastia — proliferation of ductal and stromal glandular tissue in the retroareolar plane. Classic presentation: firm, disc-shaped lesion directly behind the nipple, usually tender, usually bilateral but may be unilateral. Estrogen-driven or progestogen-sensitised. Pseudogynaecomastia — adipose accumulation in the chest without glandular proliferation. No distinct retroareolar mass on palpation; softer tissue continuous with surrounding chest fat; not tender. SERM and AI have no effect because no estrogen-driven pathology is present. The intervention is caloric deficit. Pathological breast mass — the uncommon&hellip;